Information  X 
Enter a valid email address

Babcock Intnl Group (BAB)

  Print          Annual reports

Thursday 06 January, 2022

Babcock Intnl Group

Director Appointment

RNS Number : 5736X
Babcock International Group PLC
06 January 2022
 

Director appointment

 

6 January 2022

 

Babcock International Group PLC ("Babcock" or "the Group") is pleased to announce the appointment of John Ramsay as Non-Executive Director with immediate effect.

 

John, a Chartered Accountant, brings with him over 30 years of international business and finance experience. He served as Chief Financial Officer of Syngenta AG from 2007 to 2016, and interim Chief Executive Officer of Syngenta from October 2015 to June 2016. Prior to joining Syngenta, he held senior international finance roles with Zeneca Agrochemicals and ICI.

 

John is a member of the Supervisory Board at Koninklijke DSM N.V. and is a Non-Executive Director of Croda International PLC and RHI Magnesita N.V. He is Audit Committee Chair at each of these companies. He was Non-Executive Director and Audit Chair of G4S PLC until April 2021.

 

 

Ends

 

 

For further information:

 

Andrew Gollan, Director of Investor Relations

+44 (0)7936 039004

Kate Hill, Group Director of Communications

+44 (0)20 7355 5312



Tulchan Communications


Olivia Peters / Harry Cameron

+44 (0)20 7353 4200  

 

 

 

Notes

 

There are no further matters to be disclosed under LR9.6.13R of the Listing Rules of the UK Listing Authority.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAEAEFSEFXAEAA

a d v e r t i s e m e n t